Simple blood test could spot patients most at risk of dying from heart failure, study suggests
Experts believe measuring levels of neuropeptide Y (NPY) could help predict how heart failure is likely to progress and therefore identify patients at most risk of dying. (Source: the Mail online | Health)
Source: the Mail online | Health - March 17, 2024 Category: Consumer Health News Source Type: news

Groups aim to standardize nuclear medicine imaging of CV infections
Eleven medical associations have released guidance on the use of PET/CT and SPECT/CT for patients with cardiovascular (CV) infections. The recommendations could improve patient care, as current clinical tools are often insufficient in complicated cases, noted lead author of the guidance Jamieson Bourque, MD, of the University of Virginia Health System in Charlottesville. The document was published jointly March 11 in the Journal of Nuclear Cardiology, Clinical Infectious Diseases, the Heart Rhythm Journal, and JACC: Cardiovascular Imaging. “The stakes are high with cardiovascular infection because the incidence is incr...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news

'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drug
A University of Cincinnati cardiologist founded a company after making a breakthrough discovery that could save lives, thanks to a drug that's been hiding in plain sight for a century. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 14, 2024 Category: Pharmaceuticals Authors: Brian Planalp Source Type: news

What's New in HFrEF Treatment: ACC Consensus Guidance What's New in HFrEF Treatment: ACC Consensus Guidance
A new " Expert Consensus Decision Pathway " provided a practical, streamlined update to frontline clinicians treating heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 14, 2024 Category: Cardiology Tags: Cardiology Source Type: news

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds
Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complicationsCovid vaccinations substantially reduce the risk of heart failure and potentially dangerous blood clots linked to the infection for up to a year, according to a large study.Researchers analysed health records from more than 20 million people across the UK, Spain and Estonia and found consistent evidence that the jabs protected against serious cardiovascular complications of the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 12, 2024 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Science Health Vaccines and immunisation World news Infectious diseases Society Source Type: news

Why Is Mesoblast Stock Trading Higher On Monday?
Monday, Mesoblast Limited MESO announced that the FDA supports an accelerated approval pathway for rexlemestrocel-L, its allogeneic mesenchymal precursor cell product, for end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). In the…#mesoblastlimited #fda #lvadmpcstudy #lvad #stro3 #weans #mesoblast #lvads #meso (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2024 Category: Consumer Health News Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news

2 Bay Area biotechs look to raise collective $550 million following deal, trial news
Akero disclosed midstage trial data Monday for its treatment for the fatty liver disease MASH, while BridgeBio announced a deal Sunday to license its heart failure drug to Bayer in Europe. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 4, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Bayer, BridgeBio in big-bucks deal with heart failure drug
The deal is a win for BridgeBio and CEO Neil Kumar and represents one of the first wins for Bayer CEO Bill Anderson a year into his tenure. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 4, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

This sign in your feet could indicate heart failure - what to look for
If you spot this sign you should speak to your GP. (Source: Daily Express - Health)
Source: Daily Express - Health - March 3, 2024 Category: Consumer Health News Source Type: news

Can Postpartum BP Control Lower Heart Failure Risk? Can Postpartum BP Control Lower Heart Failure Risk?
A study looks at whether the adverse cardiac remodeling during a hypertensive pregnancy can be reversed with optimal blood pressure control in the postpartum period.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2024 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Ready-to-Eat Food Environment Linked to Risk for Heart Failure
WEDNESDAY, Feb. 28, 2024 -- Exposure to ready-to-eat food environments is associated with a higher risk for incident heart failure, according to a study published online Feb. 27 in Circulation: Heart Failure. Qiaochu Xue, M.P.H., from the School of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2024 Category: Pharmaceuticals Source Type: news

Mom's Grief During Pregnancy Could Pass Heart Trouble to Her Child
WEDNESDAY, Feb. 28, 2024 -- Babies born to mothers who experience profound grief during pregnancy may be vulnerable to heart failure much later in life, new research suggests. " If future studies support our findings, the implementation of early... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 28, 2024 Category: General Medicine Source Type: news

From the university of the extremely obvious... living near pubs and bars is BAD for your health (because you spend too much time there!)
People who live in 'high density' areas, with 11 or more venues within easy walking distance, had a 16 per cent higher risk of suffering heart failure. The study was conducted in the US using UK data. (Source: the Mail online | Health)
Source: the Mail online | Health - February 27, 2024 Category: Consumer Health News Source Type: news